Jeffrey A. Bluestone, PhD

---

Education

Cook College, Rutgers University, B.S., 1974, Biology
Rutgers - State University, NJ, M.S., 1977, Microbiology
Cornell Graduate School of Medical Science (Sloan-Kettering Division), Ph.D., 1980, Immunology

---

Professional Experience

• 1980-1982
  Anna Fuller Fund Postdoctoral Fellow, Immunology Branch, National Cancer Institute, NIH
• 1982-1982
  Laboratory Leader, Senior Staff Fellow, Transplantation Biology Section, Immunology Branch, NCI, NIH
• 1986-1982
  Senior Investigator, Transplantation Biology Section, Immunology Branch, NCI, NIH
• 1987-1992
  Associate Professor, Ben May Institute, Dept. of Pathology and the Committee on Immunology, University of Chicago
• 1991-2002
  Professor, Ben May Institute, Department of Pathology and the Committee on Immunology, University of Chicago and Chairman, Committee on Immunology
• 1995-2002
  Director, Ben May Institute for Cancer Research
• 1999-present
  Director, Juvenile Diabetes Center, University of Chicago and University of Minnesota
• 1999-present
  Director, Immune Tolerance Network
• 2000-present
  A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology; and Director, UCSF Diabetes Center, the Metabolic Research Unit and the Hormone Research Institute, UCSF

---

Honors & Awards

• 1987-1982
  Gould Foundation Faculty Scholar
• 1982
  American Cancer Society Faculty Scholar
• 1992
  Guggenheim Senior Fellowship
• 1992
  Fogarty Senior Research Fellowship
• 1992
  Cornell Medical School - Distinguished Alumni Award
• 2002
  Priscilla White Lecturer, Brigham & Women's Hospital, Joslin Diabetes Center
• 2002
  Juvenile Diabetes Research Foundation Gerold & Kayla Grodsky Basic Science Award
• 2002
  American Society for Transplantation Roche Distinguished Research Award
• 2002
  Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award, Juvenile Diabetes Research Foundation
• 2002
  Elected, American Academy of Arts and Sciences

---

Selected Publications

1. Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. Immunol Rev. 2013 May; 253(1):65-81.
   View on PubMed
2. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 3; 5(179):179ps7.
   View on PubMed
3. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013 Apr; 14(4):307-8.
   View on PubMed
4. Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. Cutting Edge: A Novel, Human-Specific Interacting Protein Couples FOXP3 to a Chromatin-Remodeling Complex That Contains KAP1/TRIM28. J Immunol. 2013 May 1; 190(9):4470-3.
   View on PubMed
5. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Mar 1; 13(4):243-56.
   View on PubMed
6. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. Immune Therapy and ß-Cell Death in Type 1 Diabetes. Diabetes. 2013 May; 62(5):1676-80.
   View on PubMed
7. Stumpf M, Zhou X, Bluestone JA. The b7-independent isoform of ctla-4 functions to regulate autoimmune diabetes. J Immunol. 2013 Feb 1; 190(3):961-9.
   View on PubMed
8. Bluestone JA, Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol. 2012; 4(11).
   View on PubMed
9. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400.
   View on PubMed
10. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3(+) HELIOS(+) regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67.
    View on PubMed
11. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012 Sep 24; 209(10):1713-22, S1-19.
    View on PubMed
12. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett. 2012 Aug 8; 12(8):4018-24.
    View on PubMed
13. Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8.
    View on PubMed
14. Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12668-73.
    View on PubMed
15. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes. 2012 Sep; 61(9):2340-8.
    View on PubMed
16. Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA. MicroRNA 10a marks regulatory T cells. PLoS One. 2012; 7(5):e36684.
    View on PubMed
17. Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One. 2012; 7(4):e36011.
    View on PubMed
18. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, McManus MT. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 2012 Apr 19; 1(4):385-91.
    View on PubMed
19. Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a007807.
    View on PubMed
20. Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012 Feb; 4(1):11-21.
    View on PubMed

View on UCSF Profiles